Learn about the discovery of immunodeficiencies leading to the use of pooled immunoglobulin as therapy, the struggle to use it intravenously and the eventual use in autoimmune disease. Intro :11 In this episode :15 Splitting Part 3 into two episodes :26 Part A of the history of IV Ig and the antibody :53 A recap on Cohn fractionation 2:40 The history and uses of IV Ig 4:30 What led to the recognition and research of primary immunodeficiencies 7:08 How Charles Janeway Sr. paved the way for IV Ig from intramuscular Ig 9:01 What are protein aggregates? 12:54 Understanding the various mechanisms of Ig reactions 15:49 Managing patients with low IgA and anti-IgA antibodies 18:36 How to go from treating immunodeficiency to treating autoimmunity 21:40 The modern understanding and mystery of IV Ig 25:30 Quick summary 26:05 Thanks for listening! 27:30 Disclosure: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Barandun S, et al. Vox Sang. 1962;7:157-174. Eibl MM. Immunol Allergy Clin North Am. 2008;28:737-764, viii. Furusho K, et al. Lancet. 1983;2:1359. Gallagher PE, Buckley RH. J Allergy Clin Immunol. 1982;69:120. Guo Y, et al. Front Immunol. 2018;9:1299. Imbach P, et al. Lancet. 1981;1:1228-31. Intravenous Immunoglobulin: Prevention and Treatment of Disease. NIH Consens Statement Online. 1990;8:1-23. Kustiawan I. PLoS ONE. 2018;13: e0195729. https://doi.org/10.1371/journal.pone.0195729. MRC Working Party on Hypogammaglobulinaemia. Hypogammaglobulinaemia in the United Kingdom. London: Her Majesty’s Stationery Office; 1971. Oransky I. Lancet. 2003;362:409. Sandler SG, et al. Transfus Med Rev. 1995;9:1-8.